XML 38 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity
12 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Equity/(Deficit)
At June 30, 2023 and 2022, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares”. Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2023 and 2022.
We repurchased $3.1 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2023, 2022 and 2021, as described below. We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.
During fiscal 2023, we repurchased 24.6 million common shares having an aggregate cost of $1.9 billion. We repurchased 13.6 million, 3.2 million, 3.2 million and 4.6 million common shares under multiple accelerated share repurchase ("ASR") programs with average prices paid per common share of $73.36, $77.50, $77.27 and $87.18, respectively. These repurchases began on September 14, 2022 and we expect the most recent program to conclude in August 2023.
During fiscal 2022, we repurchased 19.5 million common shares having an aggregate cost of $1.0 billion. We repurchased 9.8 million, 6.1 million and 3.6 million common shares under multiple ASR programs with average prices paid per common share of $51.10, $49.39 and $56.02, respectively. These repurchases began on August 18, 2021 and concluded on April 18, 2022.
During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an ASR program, which began on February 9, 2021 and was completed on March 31, 2021.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments and Other
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2021$(46)$12 $(34)
Other comprehensive loss, before reclassifications(56)(16)(72)
Amounts reclassified to earnings— (8)(8)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $24 million
(56)(24)(80)
Balance at June 30, 2022(102)(12)(114)
Other comprehensive loss, before reclassifications(35)12 (23)
Amounts reclassified to earnings— (14)(14)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax benefit of $2 million
(35)(2)(37)
Balance at June 30, 2023$(137)$(14)$(151)